Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Shanghai RAAS Blood Products Co., Ltd. clinical trials
Part of Haier Group, which holds 29.90% of voting rights as of 2025-12-31. Source
The registry lists 4 studies whose lead sponsor is Shanghai RAAS Blood Products Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Shanghai RAAS Blood Products Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Shanghai RAAS Blood Products Co., Ltd..
- Shanghai RAAS Blood Products Co., Ltd.4 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 4 of 4.
- A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With HemophiliaNot yet recruitingNCT07876674Phase 3
- A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII DeficiencyNot yet recruitingNCT07711158Phase 2
- An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII DeficiencyRecruitingNCT07644832Phase 1/2
- A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand DiseaseRecruitingNCT07640893Phase 2